Diabetes drugs could become an effective way to treat behavioral issues and addiction.
WSJ’s Daniela Hernandez breaks down the science on how they work and how they could change psychiatry forever.
Photo illustration: Elizabeth SmelovWegovy maker Novo Nordisk reported soaring profit, boosted by blockbuster weight-loss drugs that have quickly made the Danish drugmaker Europe’s most valuable company.
Surging demand for the drugs has supercharged the company’s stock price, tilted the scales of its home economy in Denmark and triggered a frenzy on Wall Street over how the treatments and others like it might affect other industries, including snack foods and airlines.
Persons:
WSJ’s Daniela Hernandez, Elizabeth Smelov
Organizations:
Novo Nordisk
Locations:
Danish, Denmark